Evobrutinib drug interaction study completed in healthy volunteers

NCT ID NCT05064488

Completed Knowledge-focused Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study tested how multiple doses of evobrutinib, an experimental drug, affect the way the body processes four common medications: digoxin, metformin, rosuvastatin, and sumatriptan. Forty healthy adults participated in two parts, receiving evobrutinib along with single doses of these drugs. The goal was to measure drug levels in the blood and check for side effects, helping to guide future use of evobrutinib.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Evobrutinib
What this could lead to: If successful, this study could help doctors understand how evobrutinib interacts with common medications, guiding safer use in future patients.
What could go wrong: This is an early-phase, drug-interaction study in healthy volunteers, not a treatment trial. Results may not predict effects in patients or lead to any new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Nuvisan GmbH

Neu-Ulm, 89231, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.